GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Immuno & Safety Study With 2 Formulations of DTPw-HBV/HIB When Given at Birth With Hepatitis B at 2, 4 and 6 Mths.Age.
Phase 3
Terminated
- Conditions
- TetanusDiphtheriaHepatitis BHaemophilus Influenzae Type bWhole Cell Pertussis
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 288
- Registration Number
- NCT00316680
- Locations
- 🇩🇴
GSK Investigational Site, Santo Domingo, Dominican Republic
Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine
Phase 2
Completed
- Conditions
- Infections, Papillomavirus
- Interventions
- Biological: Aimmugen™Biological: HPV-16/18 vaccine (Cervarix™)
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1046
- Registration Number
- NCT00316693
- Locations
GSK Investigational Site
Sexual Functioning Study With Antidepressants
Phase 4
Completed
- Conditions
- Major Depressive Disorder (MDD)Depressive Disorder, Major
- First Posted Date
- 2006-04-20
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 347
- Registration Number
- NCT00316160
- Locations
- 🇺🇸
GSK Investigational Site, Middleton, Wisconsin, United States
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
Phase 2
Completed
- Conditions
- Ovarian CancerNeoplasms, Ovarian
- Interventions
- First Posted Date
- 2006-04-20
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 77
- Registration Number
- NCT00316173
- Locations
- 🇨🇦
GSK Investigational Site, Quebec, Canada
Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules
Phase 3
Completed
- Conditions
- Haemophilus Influenzae Type bPoliomyelitisDiphtheriaHepatitis BAcellular PertussisTetanus
- First Posted Date
- 2006-04-20
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 224
- Registration Number
- NCT00316147
- Locations
- 🇮🇳
GSK Investigational Site, New Delhi, India
First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin
- First Posted Date
- 2006-04-20
- Last Posted Date
- 2015-05-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 33
- Registration Number
- NCT00316186
- Locations
- 🇵🇱
GSK Investigational Site, Poznan, Poland
A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma
Phase 1
Completed
- Conditions
- Lymphoma, Follicular
- Interventions
- Biological: Follicular Lymphoma
- First Posted Date
- 2006-04-19
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT00315731
Viapaed Study In Children And Adolescents With Asthma
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2006-04-19
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 285
- Registration Number
- NCT00315744
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
Phase 3
Completed
- Conditions
- Restless Legs Syndrome (RLS)Restless Legs Syndrome
- First Posted Date
- 2006-04-17
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 568
- Registration Number
- NCT00314860
- Locations
- 🇬🇧
GSK Investigational Site, Ledbury, United Kingdom
Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 503
- Registration Number
- NCT00312013
- Locations
- 🇸🇮
GSK Investigational Site, Ljubljana, Slovenia
© Copyright 2025. All Rights Reserved by MedPath